Dr. Reddy's Laboratories Ltd.

BSE

Price on BSE 05 Mar,15:29 LIVE

1,307.00

+15.85

(+1.23%)

Volume :
49,421.00

Prev Close :
1,291.15

Day's H/L (Rs.) :
1,321.50 - 1,291.20

52wk H/L (Rs.) :
1,377.95 - 1,025.90

Mkt Cap (Rs. Cr) :
109,082.22

NSE

Price on NSE 05 Mar,15:57 LIVE

1,313.50

+22.30

(+1.73%)

Volume :
1,060,509.00

Prev Close :
1,291.20

Day's H/L (Rs.) :
1,322.10 - 1,292.50

52wk H/L (Rs.) :
1,379.70 - 1,020.00

Mkt Cap (Rs. Cr) :
0.00

Market News

HUL tops sustainability rankings as India Inc deepens ESG focus
Rediff.com 19 Feb 2026

Non-US uptick seen driving gains for Dr Reddy's Labs
Rediff.com 23 Jan 2026

Dr Reddy's profit down 14% on low Lenalidomide US sales
Rediff.com 22 Jan 2026

Domestic sales a booster dose for pharma revenues
Rediff.com 19 Jan 2026

'India Should Move Quickly As Conditions Change'
Rediff.com 02 Jan 2026

Report Card - Dr. Reddy's Laboratories Ltd.

PE Ratios

20.13

EPS (Rs.)

64.14

Sales (Rs. Cr)

4,282.70

Face Value (Rs.)

Net Profit Margin(%)

23.14

Last Bonus

1:1

Last Dividend(%)

800

Return on Average Equity

18.53

News for Dr. Reddy's Laboratories Ltd.

Dr Reddy''s: US SEC Ends Investigation

US SEC concludes investigation into Dr Reddy''s. No enforcement action recommended after probe into improper payments allegations.

Feb 24, 2026 21:16

Dr Reddy''s Enters Hormone Replacement Therapy

Dr Reddy''s acquires Progynova & Cyclo-Progynova for USD 32.15 mn, entering the hormone replacement therapy market in India. Strengthens gynaecology portfolio.

Feb 19, 2026 08:58

Dr Reddy''s Q3 Profit Dips 14% to Rs 1,210 Cr

Dr Reddy''s Q3FY26 profit declines 14% to Rs 1,210 crore due to lower US sales. Revenue rises to Rs 8,727 crore. India sales up 19%.

Jan 21, 2026 18:20

Dr Reddy''s & Immutep Ink Cancer Drug Licensing Pact

Dr Reddy''s and Immutep collaborate to develop and commercialize Eftilagimod Alfa (Efti), a cancer medication, outside key markets.

Dec 08, 2025 14:49

Dr Reddy''s Biosimilar Approved in Europe

Dr Reddy''s gets EU nod for AVT03, a biosimilar of Prolia (denosumab) and Xgeva, used to treat osteoporosis and prevent bone complications.

Nov 24, 2025 17:22

More News for Dr. Reddy's Laboratories Ltd. »

News for Pharmaceuticals and health care

Noida Airport Gets Security Clearance for Licence

Noida International Airport receives security clearance from BCAS, paving the way for aerodrome licence. Operations to begin soon.

Mar 05, 2026 22:45

IBM Launches Innovation Center in India

IBM launches Sangam Infrastructure Innovation Centre in India to co-create AI solutions with clients and partners.

Mar 05, 2026 22:14

UPL Restructuring: Retains Speciality Chemical Revenue

UPL Ltd to retain revenue from Superform after restructuring. Aims to create UPL Global, a pure-play crop protection platform.

Mar 05, 2026 22:10

Samsung India R&D & Galaxy S26 Development

Samsung's India R&D centers played a key role in Galaxy S26 development. Bengaluru & Noida centers crucial for AI & localization.

Mar 05, 2026 21:58

Australia Pitches for India Trade & Aviation Links

Australian official calls for increased direct trade and aviation links with India, citing growth from the free trade deal.

Mar 05, 2026 21:54

More News »

Top News

BEL & Bellatrix to Develop VLEO Technologies

BEL and Bellatrix Aerospace partner to develop satellite technologies for Very Low Earth Orbit (VLEO). Advancing India's space capabilities.

Mar 05, 2026 23:17

Noida Airport Gets Security Clearance for Licence

Noida International Airport receives security clearance from BCAS, paving the way for aerodrome licence. Operations to begin soon.

Mar 05, 2026 22:45

Fractal Analytics Q3 Profit Rises 8.5% to Rs 100 Cr

Fractal Analytics reports 8.5% profit growth to Rs 100 crore in Q3 2025. Revenue up 21% driven by healthcare and financial services.

Mar 05, 2026 22:34